Wilbanks Smith & Thomas Asset Management LLC Has $328,000 Holdings in Zoetis Inc (ZTS)
Wilbanks Smith & Thomas Asset Management LLC decreased its position in shares of Zoetis Inc (NYSE:ZTS) by 26.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,558 shares of the company’s stock after selling 1,599 shares during the period. Wilbanks Smith & Thomas Asset Management LLC’s holdings in Zoetis were worth $328,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Zoetis in the fourth quarter worth about $108,000. Steward Partners Investment Advisory LLC bought a new position in shares of Zoetis in the third quarter worth about $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Zoetis by 251.9% in the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after purchasing an additional 1,360 shares during the last quarter. Shine Investment Advisory Services Inc. grew its holdings in shares of Zoetis by 86.5% in the third quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock worth $143,000 after purchasing an additional 1,040 shares during the last quarter. Finally, McKinley Carter Wealth Services Inc. bought a new position in shares of Zoetis in the third quarter worth about $201,000. Institutional investors and hedge funds own 93.72% of the company’s stock.
A number of research analysts have recently commented on the stock. BMO Capital Markets set a $78.00 price target on shares of Zoetis and gave the stock a “hold” rating in a report on Monday, January 22nd. Piper Jaffray Companies restated a “buy” rating and issued a $86.00 price target on shares of Zoetis in a report on Thursday, January 18th. Jefferies Group restated a “buy” rating and issued a $89.00 price target on shares of Zoetis in a report on Tuesday, January 16th. Zacks Investment Research cut shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price target on the stock. in a report on Saturday, January 13th. Finally, Cantor Fitzgerald set a $85.00 price target on shares of Zoetis and gave the stock a “buy” rating in a report on Thursday, January 11th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the company. Zoetis currently has a consensus rating of “Buy” and a consensus target price of $73.72.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be given a $0.126 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. This represents a $0.50 annualized dividend and a dividend yield of 0.69%. The ex-dividend date is Thursday, January 18th. Zoetis’s dividend payout ratio (DPR) is presently 26.32%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.